UK Markets close in 4 mins

Unaudited NAV and Notice of Financial Results

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Arix Bioscience PLC (ARIX)
Unaudited NAV and Notice of Financial Results
29-Apr-2022 / 10:44 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

 

PRESS RELEASE

Arix Bioscience plc

 

Unaudited NAV and Notice of Financial Results

 

LONDON, 29 April 2022: Arix Bioscience plc ("Arix" or the "Company") (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited NAV of the Company as follows:

 

Date

NAV Breakdown

Total NAV

 

NAV per share

Listed Portfolio

Unlisted Portfolio

Cash

Other Interests

31-Dec-21

£63.3m

£54.6m

£134.2m

£3.3m

£255.4m

 

£1.98

31-Mar-22

£53.5m

£57.2m

£127.8m

£2.8m

£241.3m

 

£1.87

 

 

In line with the reconstituted Board's desire to improve corporate governance and transparency, and with the current balance of public companies within the portfolio, Arix intends to provide regular market updates on its unaudited NAV and is therefore today also releasing its position as of 31 March 2022.

 

Arix will announce its results for the full year ended 31 December 2021, on 5 May 2022 utilising the FCA's temporary relief from reporting deadlines due to the impact of the Covid-19 pandemic.  The Board does not expect any material changes to the NAV for the year ended 31 December 2021 on publication of the audited financial results. 

 

The Company will also host a virtual analyst presentation followed by a Q&A session at 12pm GMT on 5 May. Analysts and investors who wish to participate should visit this link to register.

 

The webcast of the presentation will be available on the Investor Relations section of the Company's website at https://arixbioscience.com/investor-relations/events-presentations

 

For any details of the webcast or conference call please contact:  arix@powerscourt-group.com

 

 

[ENDS]

 

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil

+44 (0)20 7250 1446

arix@powerscourt-group.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotech companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 


ISIN:

GB00BD045071

Category Code:

NOR

TIDM:

ARIX

LEI Code:

213800OVT3AHQCXNIX43

OAM Categories:

3.1. Additional regulated information required to be disclosed under the laws of a Member State

Sequence No.:

158688

EQS News ID:

1339853


 

End of Announcement

EQS News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting